Literature DB >> 11418633

Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells.

H Shirota1, K Sano, N Hirasawa, T Terui, K Ohuchi, T Hattori, K Shirato, G Tamura.   

Abstract

Oligodeoxynucleotides containing CpG motifs have been highlighted as potent Th1 activators. We previously reported that Ag and CpG, when conjugated together, synergistically promoted the Ag-specific Th1 development and inhibited the Th2-mediated airway eosinophilia. In this study, we examined the mechanisms underlying the synergism of the covalent conjugation. The CpG-OVA conjugate enhanced the Th1 activation and development. These characteristic features of the conjugate could not be ascribed to the polymerization of OVA, but mirrored the augmented binding of the CpG-tagged Ag to dendritic cells (DCs) in a CpG-guided manner, because phycobiliprotein, R-PE, conjugated to CpG stained a higher proportion of DCs with higher intensity than the mixture. R-PE fluorescence was emitted from cytoplasmic portions of the DCs, which simultaneously expressed costimulatory molecules and IL-12. The CpG-conjugated R-PE trafficking described above actually served as a potent Ag. These results indicate that CpG conjugated to Ag exhibit novel joint properties as promoters of Ag uptake and DC activators, thereby potentiating the ability of DCs to generate Th1 cells. The DNA-mediated promotion of Ag uptake would be advantageous for evoking host immune responses against invading microorganisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418633     DOI: 10.4049/jimmunol.167.1.66

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Use of locked nucleic acid oligonucleotides to add functionality to plasmid DNA.

Authors:  Kirsten M L Hertoghs; Jonathan H Ellis; Ian R Catchpole
Journal:  Nucleic Acids Res       Date:  2003-10-15       Impact factor: 16.971

2.  CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.

Authors:  Sungyoul Hong; Jianfei Qian; Haiyan Li; Jing Yang; Yong Lu; Yuhuan Zheng; Qing Yi
Journal:  Cancer Immunol Immunother       Date:  2011-10-15       Impact factor: 6.968

3.  A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.

Authors:  Melissa Santone; Susanna Aprea; Tom Y H Wu; Michael P Cooke; M Lamine Mbow; Nicholas M Valiante; James S Rush; Stephanie Dougan; Ana Avalos; Hidde Ploegh; Ennio De Gregorio; Cecilia Buonsanti; Ugo D'Oro
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Conjugation of lipid and CpG-containing oligonucleotide yields an efficient method for liposome incorporation.

Authors:  Chasity D Andrews; Chester J Provoda; Gary Ott; Kyung-Dall Lee
Journal:  Bioconjug Chem       Date:  2011-06-15       Impact factor: 4.774

5.  Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice.

Authors:  Joe Inoue; Satoshi Yotsumoto; Takatoshi Sakamoto; Seishi Tsuchiya; Yukihiko Aramaki
Journal:  Pharm Res       Date:  2005-09-26       Impact factor: 4.200

6.  TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens.

Authors:  Hidekazu Shirota; Dennis M Klinman
Journal:  Methods Mol Biol       Date:  2014

7.  HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.

Authors:  Ulrike Wille-Reece; Barbara J Flynn; Karin Loré; Richard A Koup; Ross M Kedl; Joseph J Mattapallil; Walter R Weiss; Mario Roederer; Robert A Seder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-11       Impact factor: 11.205

8.  Contribution of interferon-beta to the immune activation induced by double-stranded DNA.

Authors:  Hidekazu Shirota; Ken J Ishii; Hiroki Takakuwa; Dennis M Klinman
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

Review 9.  Innate immunity.

Authors:  Stuart E Turvey; David H Broide
Journal:  J Allergy Clin Immunol       Date:  2009-11-24       Impact factor: 10.793

Review 10.  Immunomodulation of allergic disease.

Authors:  David H Broide
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.